|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MBP |
Gene summary for MBP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MBP | Gene ID | 4155 |
| Gene name | myelin basic protein | |
| Gene Alias | MBP | |
| Cytomap | 18q23 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P02686 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4155 | MBP | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.79e-03 | -2.52e-01 | 0.0155 |
| 4155 | MBP | HTA11_347_2000001011 | Human | Colorectum | AD | 1.26e-03 | 3.58e-01 | -0.1954 |
| 4155 | MBP | HTA11_411_2000001011 | Human | Colorectum | SER | 3.67e-02 | 7.88e-01 | -0.2602 |
| 4155 | MBP | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.56e-03 | -2.75e-01 | 0.3005 |
| 4155 | MBP | F007 | Human | Colorectum | FAP | 1.61e-03 | -3.40e-01 | 0.1176 |
| 4155 | MBP | A001-C-207 | Human | Colorectum | FAP | 8.58e-06 | -2.89e-01 | 0.1278 |
| 4155 | MBP | A015-C-203 | Human | Colorectum | FAP | 4.63e-27 | -4.07e-01 | -0.1294 |
| 4155 | MBP | A015-C-204 | Human | Colorectum | FAP | 5.91e-07 | -3.66e-01 | -0.0228 |
| 4155 | MBP | A014-C-040 | Human | Colorectum | FAP | 3.63e-04 | -3.82e-01 | -0.1184 |
| 4155 | MBP | A002-C-201 | Human | Colorectum | FAP | 6.35e-18 | -4.80e-01 | 0.0324 |
| 4155 | MBP | A002-C-203 | Human | Colorectum | FAP | 4.79e-06 | -2.30e-01 | 0.2786 |
| 4155 | MBP | A001-C-119 | Human | Colorectum | FAP | 1.71e-05 | -3.45e-01 | -0.1557 |
| 4155 | MBP | A001-C-108 | Human | Colorectum | FAP | 3.68e-16 | -3.49e-01 | -0.0272 |
| 4155 | MBP | A002-C-205 | Human | Colorectum | FAP | 8.93e-22 | -4.59e-01 | -0.1236 |
| 4155 | MBP | A001-C-104 | Human | Colorectum | FAP | 4.55e-04 | -2.50e-01 | 0.0184 |
| 4155 | MBP | A015-C-005 | Human | Colorectum | FAP | 4.24e-02 | -1.36e-01 | -0.0336 |
| 4155 | MBP | A015-C-006 | Human | Colorectum | FAP | 2.82e-15 | -4.64e-01 | -0.0994 |
| 4155 | MBP | A015-C-106 | Human | Colorectum | FAP | 3.41e-14 | -2.77e-01 | -0.0511 |
| 4155 | MBP | A002-C-114 | Human | Colorectum | FAP | 4.57e-16 | -3.91e-01 | -0.1561 |
| 4155 | MBP | A015-C-104 | Human | Colorectum | FAP | 3.43e-30 | -3.25e-01 | -0.1899 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005254816 | Endometrium | AEH | regulation of endopeptidase activity | 76/2100 | 432/18723 | 4.42e-05 | 7.43e-04 | 76 |
| GO:004885710 | Endometrium | AEH | neural nucleus development | 18/2100 | 64/18723 | 1.65e-04 | 2.15e-03 | 18 |
| GO:001095015 | Endometrium | AEH | positive regulation of endopeptidase activity | 37/2100 | 179/18723 | 1.66e-04 | 2.16e-03 | 37 |
| GO:000189410 | Endometrium | AEH | tissue homeostasis | 50/2100 | 268/18723 | 2.04e-04 | 2.54e-03 | 50 |
| GO:003090110 | Endometrium | AEH | midbrain development | 22/2100 | 90/18723 | 3.09e-04 | 3.48e-03 | 22 |
| GO:00602499 | Endometrium | AEH | anatomical structure homeostasis | 55/2100 | 314/18723 | 5.27e-04 | 5.32e-03 | 55 |
| GO:00018198 | Endometrium | AEH | positive regulation of cytokine production | 71/2100 | 467/18723 | 4.76e-03 | 3.02e-02 | 71 |
| GO:00071627 | Endometrium | AEH | negative regulation of cell adhesion | 49/2100 | 303/18723 | 5.43e-03 | 3.37e-02 | 49 |
| GO:004586217 | Endometrium | EEC | positive regulation of proteolysis | 83/2168 | 372/18723 | 2.32e-09 | 1.86e-07 | 83 |
| GO:005254717 | Endometrium | EEC | regulation of peptidase activity | 91/2168 | 461/18723 | 2.00e-07 | 8.93e-06 | 91 |
| GO:005254817 | Endometrium | EEC | regulation of endopeptidase activity | 82/2168 | 432/18723 | 3.96e-06 | 1.04e-04 | 82 |
| GO:002240715 | Endometrium | EEC | regulation of cell-cell adhesion | 84/2168 | 448/18723 | 4.98e-06 | 1.24e-04 | 84 |
| GO:001095217 | Endometrium | EEC | positive regulation of peptidase activity | 44/2168 | 197/18723 | 1.25e-05 | 2.54e-04 | 44 |
| GO:003563314 | Endometrium | EEC | maintenance of blood-brain barrier | 14/2168 | 35/18723 | 1.62e-05 | 3.14e-04 | 14 |
| GO:000963615 | Endometrium | EEC | response to toxic substance | 54/2168 | 262/18723 | 1.65e-05 | 3.18e-04 | 54 |
| GO:002176216 | Endometrium | EEC | substantia nigra development | 16/2168 | 44/18723 | 1.71e-05 | 3.26e-04 | 16 |
| GO:003090113 | Endometrium | EEC | midbrain development | 23/2168 | 90/18723 | 1.80e-04 | 2.21e-03 | 23 |
| GO:000189415 | Endometrium | EEC | tissue homeostasis | 51/2168 | 268/18723 | 2.34e-04 | 2.75e-03 | 51 |
| GO:004885714 | Endometrium | EEC | neural nucleus development | 18/2168 | 64/18723 | 2.47e-04 | 2.88e-03 | 18 |
| GO:001095016 | Endometrium | EEC | positive regulation of endopeptidase activity | 37/2168 | 179/18723 | 3.13e-04 | 3.48e-03 | 37 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MBP | SNV | Missense_Mutation | c.653N>G | p.Asn218Ser | p.N218S | P02686 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.987) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MBP | SNV | Missense_Mutation | c.637C>T | p.Arg213Trp | p.R213W | P02686 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-D8-A1XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| MBP | SNV | Missense_Mutation | rs529411261 | c.206N>A | p.Arg69His | p.R69H | P02686 | protein_coding | tolerated_low_confidence(0.19) | benign(0.001) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MBP | deletion | Frame_Shift_Del | c.86delN | p.Lys29ArgfsTer36 | p.K29Rfs*36 | P02686 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| MBP | deletion | Frame_Shift_Del | c.86delN | p.Lys29ArgfsTer36 | p.K29Rfs*36 | P02686 | protein_coding | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
| MBP | SNV | Missense_Mutation | rs141290653 | c.263N>A | p.Arg88His | p.R88H | P02686 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MBP | SNV | Missense_Mutation | rs745869718 | c.404N>T | p.Ala135Val | p.A135V | P02686 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.994) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MBP | SNV | Missense_Mutation | c.394G>T | p.Asp132Tyr | p.D132Y | P02686 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.855) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MBP | SNV | Missense_Mutation | novel | c.588N>A | p.His196Gln | p.H196Q | P02686 | protein_coding | tolerated_low_confidence(0.17) | probably_damaging(0.992) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MBP | SNV | Missense_Mutation | c.109N>T | p.Arg37Trp | p.R37W | P02686 | protein_coding | deleterious_low_confidence(0.01) | benign(0.312) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4155 | MBP | CELL SURFACE | BIOFLAVONOID | 9482255 | ||
| 4155 | MBP | CELL SURFACE | NBI-5788 | TIPLIMOTIDE | ||
| 4155 | MBP | CELL SURFACE | BHT-3009 | |||
| 4155 | MBP | CELL SURFACE | CSA | CYCLOSPORINE | 9184637 | |
| 4155 | MBP | CELL SURFACE | INTERFERON BETA-1A | 10932275 | ||
| 4155 | MBP | CELL SURFACE | QUERCETIN | QUERCETIN | 9482255 | |
| 4155 | MBP | CELL SURFACE | PREDNISONE | PREDNISONE | 10612091 | |
| 4155 | MBP | CELL SURFACE | INSULIN | INSULIN | 8948451 | |
| 4155 | MBP | CELL SURFACE | ATX-MS-1467 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |